Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
International Journal of Clinical Oncology
Erschienen in:

31.01.2025 | Original Article

Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium

verfasst von: Taizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Mamoru Hashimoto, Takafumi Minami, Yutaka Yamamoto, Shogo Yamazaki, Tomoaki Takai, Moritoshi Sakamoto, Yuki Nakajima, Kazuki Nishimura, Ryoichi Maenosono, Takuya Tsujino, Ko Nakamura, Tatsuo Fukushima, Kyosuke Nishio, Yuki Yoshikawa, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Kazutoshi Fujita, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2025

Einloggen, um Zugang zu erhalten

Abstract

Background

Enfortumab vedotin (EV), an antibody–drug conjugate (ADC) targeting Nectin-4, has been available as standard care for metastatic urothelial carcinoma (mUC) patients who have progressed after platinum-based chemotherapy and checkpoint inhibitors (CPIs). However, the association between body mass index (BMI) and clinical outcomes for EV remains unknown.

Methods

We analyzed the records of 123 mUC patients who received EV. The cohort was divided into low BMI (< 22, n = 65) and high BMI (≥ 22, n = 58) groups. Propensity score matching was performed to reduce clinical bias between the two groups.

Results

In the total cohort (n = 123), the objective response rate (ORR) and disease control rate (DCR) were 46% and 68%, respectively. The ORR was significantly higher in the higher BMI group (62%, n = 58) compared to the lower BMI group (32%, n = 65). Among the pair-matched cohort (n = 100), despite reducing potential bias, the ORR remained significantly higher in the higher BMI group than in the lower BMI group (64% vs. 32%, p = 0.002). Both overall survival (OS) and radiographic progression-free survival (r-PFS) were longer in the higher BMI group compared to the lower BMI group (median OS: not reached vs. 8 months, p = 0.035; median r-PFS: 10 vs. 4 months, p < 0.001). On multivariate analyses, a higher BMI (≥ 22) was an independent predictor for achieving objective response and favorable OS in mUC patients treated with EV.

Conclusions

The findings of this study suggest a potential association between high BMI and improved tumor response to EV in mUC patients with disease progression after platinum-based chemotherapy and CPIs.
Literatur
1.
Bellmunt J et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026PubMedPubMedCentral
2.
Powles T et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391(10122):748–757PubMed
3.
Loriot Y et al (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381(4):338–348PubMed
4.
Powles T et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125–1135PubMedPubMedCentral
5.
Sidaway P (2021) Sacituzumab govitecan is safe and effective. Nat Rev Clin Oncol 18(7):400PubMed
6.
Rosenberg JE et al (2023) EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 34(11):1047–1054PubMed
7.
Tomisaki I et al (2023) Association between body mass index and outcomes in patients with urothelial carcinoma treated with pembrolizumab. Anticancer Res 43(1):269–274PubMed
8.
Ishihara H et al (2023) Impact of body mass index on outcomes in an Asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. Clin Genitourin Cancer 21(1):136–145PubMed
9.
Takemura K et al (2022) Impact of body mass index on survival outcomes of patients with metastatic renal cell carcinoma in the immuno-oncology era: a systematic review and meta-analysis. Eur Urol Open Sci 39:62–71PubMedPubMedCentral
10.
Herrmann T et al (2022) Body mass index, sarcopenia, and their variations in predicting outcomes for patients treated with nivolumab for metastatic renal cell carcinoma. Oncology 100(2):114–123PubMed
11.
Boi SK et al (2020) Obesity diminishes response to PD-1-based immunotherapies in renal cancer. J Immunother Cancer 8(2):e000725PubMedPubMedCentral
12.
Fukuokaya W et al (2023) Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study. Int J Urol 31:342PubMed
13.
Uchimoto T et al (2023) Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma. BJU Int 131(4):477–485PubMed
14.
Hirasawa Y et al (2024) Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan. J Cancer Res Clin Oncol 150(4):182PubMedPubMedCentral
15.
Uchimoto T et al (2024) Durable response to enfortumab vedotin compared to re-challenging chemotherapy in metastatic urothelial carcinoma after checkpoint inhibitors. Target Oncol 19:401PubMed
16.
Taguchi S et al (2023) Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study. Int J Urol 30(12):1180–1186PubMed
17.
Miyake M et al (2024) Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. Jpn J Clin Oncol 54(3):329–338PubMed
18.
Uemura K et al (2024) Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Int J Urol 31(6):678–684PubMed
19.
Taguchi S, et al. Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: a landmark analysis. Int J Urol. 2024.
20.
Gandevia B, Tovell A (1964) Declaration of Helsinki. Med J Aust 2:320–321PubMed
21.
Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer 45(2):228–247PubMed
22.
Lysaght J, Conroy MJ (2024) The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies. Nat Rev Endocrinol 20:701PubMed
23.
Mathijssen RH, Sparreboom A (2009) Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 85(1):23PubMed
24.
Vlachou E et al (2023) Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature. Eur Urol Open Sci 49:100–103PubMedPubMedCentral
Metadaten
Titel
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium
verfasst von
Taizo Uchimoto
Kengo Iwatsuki
Kazumasa Komura
Wataru Fukuokaya
Takahiro Adachi
Yosuke Hirasawa
Takeshi Hashimoto
Atsuhiko Yoshizawa
Masanobu Saruta
Mamoru Hashimoto
Takafumi Minami
Yutaka Yamamoto
Shogo Yamazaki
Tomoaki Takai
Moritoshi Sakamoto
Yuki Nakajima
Kazuki Nishimura
Ryoichi Maenosono
Takuya Tsujino
Ko Nakamura
Tatsuo Fukushima
Kyosuke Nishio
Yuki Yoshikawa
Shutaro Yamamoto
Kosuke Iwatani
Fumihiko Urabe
Keiichiro Mori
Takafumi Yanagisawa
Shunsuke Tsuduki
Kiyoshi Takahara
Kazutoshi Fujita
Takahiro Kimura
Yoshio Ohno
Ryoichi Shiroki
Haruhito Azuma
Publikationsdatum
31.01.2025
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 4/2025
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-025-02709-1

Weitere Artikel der Ausgabe 4/2025

Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-P

  • Open Access
  • Original Article

Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions

  • Open Access
  • Original Article

Impact of HPV status on oropharyngeal cancer detection via gastrointestinal endoscopy: a retrospective study

  • Original Article

Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer

  • Original Article

Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022

  • Special Article

Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma

  • Original Article

Neu im Fachgebiet Onkologie

Nierenzellkarzinom: Daten zur Lebensqualität unter HIF-Inhibition vorgelegt

Seit wenigen Wochen ist mit Belzutifan eine neue Wirkstoffklasse beim fortgeschrittenen klarzelligen Nierenzellkarzinom in der EU zugelassen. Frisch publizierte Ergebnisse zur Lebensqualität erweitern jetzt die Datenbasis zur Risiko-Nutzen-Bewertung für den HIF-2α-Inhibitor.

Warum genderspezifische Medizin notwendig ist 

Laut Zahlen der WHO aus dem Jahr 2024 sterben zwei Frauen pro Minute an Krankheiten, die mit geschlechtsspezifischen Faktoren zusammenhängen. Außerdem wirken Medikamente bei ihnen oft anders als bei Männern. Zeit für ein genderspezifisches Denken in der Medizin.

Nach Vollremission bei Ösophagus-Ca. – Operation erstmal aussetzen?

Studienziel erreicht, dennoch viele Fragen offen. So lassen sich die Ergebnisse der SANO-Studie zur Active-Surveillance versus sofortigen Ösophagektomie nach neoadjuvanter Komplettremission zusammenfassen. Interessant sind die Daten so oder so.

Ältere Patientinnen mit Mammakarzinom – ist weniger mehr?

Etwa 40 % der Frauen mit Mammakarzinom in Deutschland erkranken nach dem 70. Lebensjahr. Dennoch sind ältere Patientinnen in klinischen Studien häufig unterrepräsentiert. Wie können Betroffene optimal behandelt werden, ohne sie zu übertherapieren oder ihnen durch eine Untertherapie Chancen zu nehmen?  

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise